Shin-Ichi Yamada1,2, Takumi Hasegawa3, Nobuhiro Yamakawa4, Masashi Tamura5, Atsushi Takizawa6, Yasumasa Kakei3, Masaya Okura7,8, Tomofumi Naruse9, Mitsunobu Otsuru9, Shin Rin10, Michihiro Ueda10, Tetsuro Yamashita11, Tadaaki Kirita4, Yoshihide Ota5, Hiroshi Kurita6. 1. Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan. shinshin@med.u-toyama.ac.jp. 2. Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Academic Assembly, University of Toyama, 2630, Sugitani, Toyama, 930-0194, Japan. shinshin@med.u-toyama.ac.jp. 3. Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine, Kobe, Japan. 4. Department of Oral and Maxillofacial Surgery, Nara Medical University, Kashihara, Japan. 5. Department of Oral and Maxillofacial Surgery, Division of Surgery, Tokai University School of Medicine, Isehara, Japan. 6. Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto, Japan. 7. The 1st Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Osaka University, Osaka, Japan. 8. Department of Oral and Maxillofacial Surgery, Saiseikai Matsusaka General Hospital, Matsuzaka, Japan. 9. Department of Clinical Oral Oncology, Unit of Translational Medicine, Course of Medical and Dental Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 10. Department of Oral and Maxillofacial Surgery, Hokkaido Cancer Center, Sapporo, Japan. 11. Department of Oral and Maxillofacial Surgery, Keiyukai Sapporo Hospital, Sapporo, Japan.
Abstract
OBJECTIVES: The purpose of this multicenter retrospective study was to investigate the demographic characteristics and treatment outcomes of patients with mucosal malignant melanoma (MM) of the oral cavity. MATERIALS AND METHODS: This was a multicenter study involving 8 Japanese universities. The medical records of 69 patients who were diagnosed with primary oral MM between January 2000 and December 2020 were retrospectively analyzed. Overall survival (OS) and prognostic factors for OS were analyzed statistically. RESULTS: There were 40 (58.0%) males and 29 (42.0%) females, and their mean (range) age was 69.8 ± 14.6 (22-96) years old. The most common primary site was the palate (30 patients, 43.5%). Stage IVA was the most common disease stage (36 patients, 52.2%). Radical therapy was performed in 55 patients (79.7%). The 2-year and 5-year OS rates of the 69 patients were 64.6% and 42.5%, respectively. The 2-year and 5-year OS rates of the stage III patients were 85.9% and 72.5%, respectively, and those of the stage IVA patients were 56.3% and 26.0%, respectively. The 1-year OS rate of the stage IVB/IVC patients was 26.7%. The 2-year and 5-year OS rates of the radical therapy group were 74.1% and 50.5%, respectively, whereas the 2-year OS rate of the non-radical therapy group was 26.0%. An advanced T classification was the only identified prognostic factor for OS (hazard ratio: 6.312, 95% confidence interval: 1.133-38.522, p < 0.05). CONCLUSIONS: Early detection and radical treatment are essential for improving the prognosis of oral MM patients. CLINICAL RELEVANCE: Early detection and adequate radical therapy leads to the better prognosis of oral MM patients.
OBJECTIVES: The purpose of this multicenter retrospective study was to investigate the demographic characteristics and treatment outcomes of patients with mucosal malignant melanoma (MM) of the oral cavity. MATERIALS AND METHODS: This was a multicenter study involving 8 Japanese universities. The medical records of 69 patients who were diagnosed with primary oral MM between January 2000 and December 2020 were retrospectively analyzed. Overall survival (OS) and prognostic factors for OS were analyzed statistically. RESULTS: There were 40 (58.0%) males and 29 (42.0%) females, and their mean (range) age was 69.8 ± 14.6 (22-96) years old. The most common primary site was the palate (30 patients, 43.5%). Stage IVA was the most common disease stage (36 patients, 52.2%). Radical therapy was performed in 55 patients (79.7%). The 2-year and 5-year OS rates of the 69 patients were 64.6% and 42.5%, respectively. The 2-year and 5-year OS rates of the stage III patients were 85.9% and 72.5%, respectively, and those of the stage IVA patients were 56.3% and 26.0%, respectively. The 1-year OS rate of the stage IVB/IVC patients was 26.7%. The 2-year and 5-year OS rates of the radical therapy group were 74.1% and 50.5%, respectively, whereas the 2-year OS rate of the non-radical therapy group was 26.0%. An advanced T classification was the only identified prognostic factor for OS (hazard ratio: 6.312, 95% confidence interval: 1.133-38.522, p < 0.05). CONCLUSIONS: Early detection and radical treatment are essential for improving the prognosis of oral MM patients. CLINICAL RELEVANCE: Early detection and adequate radical therapy leads to the better prognosis of oral MM patients.
Authors: Simple D Singh; Umed A Ajani; Christopher J Johnson; Katherine B Roland; Melody Eide; Ahmedin Jemal; Serban Negoita; Rana A Bayakly; Donatus U Ekwueme Journal: J Am Acad Dermatol Date: 2011-11 Impact factor: 11.527
Authors: Raúl González-García; Luis Naval-Gías; Pedro L Martos; Syong Hyun Nam-Cha; Francisco J Rodríguez-Campo; Mario F Muñoz-Guerra; Jesús Sastre-Pérez Journal: Med Oral Patol Oral Cir Bucal Date: 2005 May-Jul